6-8 | So called “key populations” such as sex workers and men who have sex with men have both a higher risk of contracting HIV (*1) and a lower access to antiretroviral care due to stigma and discrimination as well as, in many instances, their illegal status and high mobility. New medications to prevent HIV negative people from contracting the virus (Pre-Exposure Prophylaxis, or PreP) are a promising tool to curtail the progression of the HIV pandemic, but access remains limited in the most affected areas of Southern Africa.
MSF calls on G7 leaders to urgently address the critical gaps in global response to public health emergencies and unite to lower the price of live-saving medicines
5-26 | Two years since the first signs of the West Africa Ebola outbreak, the world today is little more prepared to respond to such an emergency than it was then, warns international humanitarian aid organisation Médecins Sans Frontières (MSF), while the lack of R&D into needed medicines and exorbitant medicine prices requires urgent and united action from the world leaders gathered in Japan. Global Health Systems: ‘Don’t build a hospital without an emergency room’ As the leaders of the G7 countries* gather in Ise-Shim
Access Campaign: Just 2% of people with the severest cases of drug-resistant TB currently have access to new, more effective treatments that could save their lives
3-21 | Two years after two new drugs to treat tuberculosis—the first in over 50 years—were conditionally approved for use, only 2% of the 150,000 people who need them have been able to access them, according to Médecins Sans Frontières (MSF).
MSF launches challenge to Pfizer’s patent on the pneumonia vaccine in India, to increase access to more affordable versions
3-11 | Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a ‘patent opposition’ in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organisations.
2-24 | More than two years after drug approved, only 180 people globally have received it. Geneva, 24 February 2016 Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of US$1,700 per treatment course.